{"entity":{"id":"incb161734","kind":"drug","name":"INCB161734","aka":[],"tldr":"INCB161734 is an experimental small-molecule drug from Incyte in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at KRAS.","summary":"INCB161734 is a small-molecule drug developed by Incyte. Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: An oral tablet identified on the trial page as a KRAS G12D inhibitor, evaluated in combination with standard chemotherapy (mFOLFIRINOX or GemNabP) versus chemotherapy alone in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07522073, plans to enrol 588 participants with primary completion expected 2028-09-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of INCB161734","url":"https://clinicaltrials.gov/search?intr=INCB161734"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07522073"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"An oral tablet identified on the trial page as a KRAS G12D inhibitor, evaluated in combination with standard chemotherapy (mFOLFIRINOX or GemNabP) versus chemotherapy alone in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/incb161734/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"trial":[{"id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/"}]}}